Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Sep;66(3):463–469. doi: 10.1038/bjc.1992.296

Interactions between human monocytes and tumour cells. Monocytes can either enhance or inhibit the growth and survival of K562 cells.

B Davies 1, S W Edwards 1
PMCID: PMC1977957  PMID: 1520583

Abstract

Human bloodstream monocytes can kill cultured tumour cells (K562), as assessed by specific release of 51Cr from the targets and by inhibition of 3H-thymidine incorporation. Confluent monolayers of monocytes were required for maximal cytotoxicity, and the density of the K562 cells was also an important factor. For example, when K562 cells were seeded at high cell densities, they were killed during incubation with monocytes, but when seeded at low cell densities their growth and survival was enhanced during culture with monocytes. The factor(s) which promoted the survival and division of low density K562 cultures was endogenously secreted from monocytes as it was present in monocyte-conditioned medium, whereas the cytotoxic factor(s) were only expressed during co-culture of monocytes with K562 cells. Conditioned medium from HL 60, U-937, HeLa and K562 could also enhance the growth and survival of low density K562 cultures, and a similar effect was also observed upon the addition of catalase and superoxide dismutase to such cultures. Thus, the monocyte:target ratio is important in determining whether monocytes exhibit cytotoxic or growth-promoting effects and hence tumour-derived or monocyte-derived reactive oxidant species may play a role in tumour cell cycle regulation.

Full text

PDF
463

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Currie G. A. Promotion of fibrosarcoma cell growth by products of syngeneic host macrophages. Br J Cancer. 1981 Oct;44(4):506–513. doi: 10.1038/bjc.1981.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dougherty G. J., McBride W. H. Accessory cell activity of murine tumor-associated macrophages. J Natl Cancer Inst. 1986 Mar;76(3):541–548. [PubMed] [Google Scholar]
  4. Drath D. B. Enhanced superoxide release and tumoricidal activity by a postlavage, in situ pulmonary macrophage population in response to activation by Mycobacterium bovis BCG exposure. Infect Immun. 1985 Jul;49(1):72–75. doi: 10.1128/iai.49.1.72-75.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edwards S. W., Say J. E., Hughes V. Gamma interferon enhances the killing of Staphylococcus aureus by human neutrophils. J Gen Microbiol. 1988 Jan;134(1):37–42. doi: 10.1099/00221287-134-1-37. [DOI] [PubMed] [Google Scholar]
  6. Fidler I. J., Darnell J. H., Budmen M. B. In vitro activation of mouse macrophages by rat lymphocyte mediators. J Immunol. 1976 Aug;117(2):666–673. [PubMed] [Google Scholar]
  7. Gorelik E., Wiltrout R. H., Copeland D., Herberman R. B. Modulation of formation of tumor metastases by peritoneal macrophages elicited by various agents. Cancer Immunol Immunother. 1985;19(1):35–42. doi: 10.1007/BF00199309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hibbs J. B., Jr Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst. 1974 Nov;53(5):1487–1492. doi: 10.1093/jnci/53.5.1487. [DOI] [PubMed] [Google Scholar]
  9. Hibbs J. B., Jr, Taintor R. R., Chapman H. A., Jr, Weinberg J. B. Macrophage tumor killing: influence of the local environment. Science. 1977 Jul 15;197(4300):279–282. doi: 10.1126/science.327547. [DOI] [PubMed] [Google Scholar]
  10. Holmes B., Page A. R., Good R. A. Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. J Clin Invest. 1967 Sep;46(9):1422–1432. doi: 10.1172/JCI105634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Inoue Y., Nelson D. S. Effect of tumour-associated macrophages on the growth of tumours in rats. Aust J Exp Biol Med Sci. 1984 Apr;62(Pt 2):181–188. doi: 10.1038/icb.1984.17. [DOI] [PubMed] [Google Scholar]
  12. Kadhim S. A., Rees R. C. Enhancement of tumor growth in mice: evidence for the involvement of host macrophages. Cell Immunol. 1984 Aug;87(1):259–269. doi: 10.1016/0008-8749(84)90150-3. [DOI] [PubMed] [Google Scholar]
  13. Lanza F., Fietta A., Spisani S., Castoldi G. L., Traniello S. Does a relationship exist between neutrophil myeloperoxidase deficiency and the occurrence of neoplasms? J Clin Lab Immunol. 1987 Apr;22(4):175–180. [PubMed] [Google Scholar]
  14. Le J., Vilcek J. Lymphokine-mediated activation of human monocytes: neutralization by monoclonal antibody to interferon-gamma. Cell Immunol. 1984 Apr 15;85(1):278–283. doi: 10.1016/0008-8749(84)90299-5. [DOI] [PubMed] [Google Scholar]
  15. Loveless S. E., Heppner G. H. Tumor-associated macrophages of mouse mammary tumors. I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors. J Immunol. 1983 Oct;131(4):2074–2078. [PubMed] [Google Scholar]
  16. McIntosh J. K., Mulé J. J., Krosnick J. A., Rosenberg S. A. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res. 1989 Mar 15;49(6):1408–1414. [PubMed] [Google Scholar]
  17. Nathan C. F., Prendergast T. J., Wiebe M. E., Stanley E. R., Platzer E., Remold H. G., Welte K., Rubin B. Y., Murray H. W. Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med. 1984 Aug 1;160(2):600–605. doi: 10.1084/jem.160.2.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Naylor M. S., Stamp G. W., Balkwill F. R. Investigation of cytokine gene expression in human colorectal cancer. Cancer Res. 1990 Jul 15;50(14):4436–4440. [PubMed] [Google Scholar]
  19. Piessens W. F., Churchill W. H., Jr, David Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. J Immunol. 1975 Jan;114(1 Pt 2):293–299. [PubMed] [Google Scholar]
  20. Reed S. G., Nathan C. F., Pihl D. L., Rodricks P., Shanebeck K., Conlon P. J., Grabstein K. H. Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med. 1987 Dec 1;166(6):1734–1746. doi: 10.1084/jem.166.6.1734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Russell S. W., Doe W. F., McIntosh A. T. Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors. J Exp Med. 1977 Dec 1;146(6):1511–1520. doi: 10.1084/jem.146.6.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schultz R. M., Kleinschmidt W. J. Functional identity between murine gamma interferon and macrophage activating factor. Nature. 1983 Sep 15;305(5931):239–240. doi: 10.1038/305239a0. [DOI] [PubMed] [Google Scholar]
  23. Steinkühler C., Mavelli I., Rossi L., Pedersen J. Z., Melino G., Weser U., Rotilio G. Cytotoxicity of a low molecular weight Cu2Zn2 superoxide dismutase active center analog in human erythroleukemia cells. Biochem Pharmacol. 1990 May 1;39(9):1473–1479. doi: 10.1016/0006-2952(90)90429-o. [DOI] [PubMed] [Google Scholar]
  24. Sun Y., Oberley L. W., Elwell J. H., Sierra-Rivera E. Antioxidant enzyme activities in normal and transformed mouse liver cells. Int J Cancer. 1989 Dec 15;44(6):1028–1033. doi: 10.1002/ijc.2910440615. [DOI] [PubMed] [Google Scholar]
  25. Yamamura Y., Fischer B. C., Harnaha J. B., Proctor J. W. Heterogeneity of murine mammary adenocarcinoma cell subpopulations. In vitro and in vivo resistance to macrophage cytotoxicity and its association with metastatic capacity. Int J Cancer. 1984 Jan 15;33(1):67–72. doi: 10.1002/ijc.2910330112. [DOI] [PubMed] [Google Scholar]
  26. Zimmerman R. J., Marafino B. J., Jr, Chan A., Landre P., Winkelhake J. L. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action. J Immunol. 1989 Feb 15;142(4):1405–1409. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES